Reply to Matters Arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease.
| Autor: | Price, Diana L., Khan, Asma, Angers, Rachel, Cardenas, Alvaro, Prato, Maria Key, Bani, Massimo, Bonhaus, Douglas W., Citron, Martin, Biere, Anja-Leona |
|---|---|
| Zdroj: | NPJ Parkinson's Disease; 3/14/2024, p1-2, 2p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink